Journal articles: 'Eradication. eng'

1

Mortimer, I. "Regaining a high health status – light at the end of the tunnel." BSAP Occasional Publication 31 (2004): 63–76. http://dx.doi.org/10.1017/s0263967x0004026x.

Full text

Abstract:

The purpose of this paper is to summarise the various means available for eliminating/eradicating disease and the economic consequences. Success rates for various diseases are discussed and summarised. A specific UK example is given to illustrate the planning and work that is required, as well as the cash flow over a twelve-month period. A typical timetable of events for eradicating/eliminating endemic diseases present in the UK and Ireland is discussed, as is the potential for regional/national eradication.

APA, Harvard, Vancouver, ISO, and other styles

2

Prowse, Thomas A. A., Phillip Cassey, Joshua V. Ross, Chandran Pfitzner, Talia A. Wittmann, and Paul Thomas. "Dodging silver bullets: good CRISPR gene-drive design is critical for eradicating exotic vertebrates." Proceedings of the Royal Society B: Biological Sciences 284, no. 1860 (August 9, 2017): 20170799. http://dx.doi.org/10.1098/rspb.2017.0799.

Full text

Abstract:

Self-replicating gene drives that can spread deleterious alleles through animal populations have been promoted as a much needed but controversial ‘silver bullet’ for controlling invasive alien species. Homing-based drives comprise an endonuclease and a guide RNA (gRNA) that are replicated during meiosis via homologous recombination. However, their efficacy for controlling wild populations is threatened by inherent polymorphic resistance and the creation of resistance alleles via non-homologous end-joining (NHEJ)-mediated DNA repair. We used stochastic individual-based models to identify realistic gene-drive strategies capable of eradicating vertebrate pest populations (mice, rats and rabbits) on islands. One popular strategy, a sex-reversing drive that converts heterozygous females into sterile males, failed to spread and required the ongoing deployment of gene-drive carriers to achieve eradication. Under alternative strategies, multiplexed gRNAs could overcome inherent polymorphic resistance and were required for eradication success even when the probability of NHEJ was low. Strategies causing homozygotic embryonic non-viability or homozygotic female sterility produced high probabilities of eradication and were robust to NHEJ-mediated deletion of the DNA sequence between multiplexed endonuclease recognition sites. The latter two strategies also purged the gene drive when eradication failed, therefore posing lower long-term risk should animals escape beyond target islands. Multiplexing gRNAs will be necessary if this technology is to be useful for insular extirpation attempts; however, precise knowledge of homing rates will be required to design low-risk gene drives with high probabilities of eradication success.

APA, Harvard, Vancouver, ISO, and other styles

3

Foucault, C., D. Raoult, and P. Brouqui. "Randomized Open Trial of Gentamicin and Doxycycline for Eradication of Bartonella quintana from Blood in Patients with Chronic Bacteremia." Antimicrobial Agents and Chemotherapy 47, no. 7 (July 2003): 2204–7. http://dx.doi.org/10.1128/aac.47.7.2204-2207.2003.

Full text

Abstract:

ABSTRACT Chronic Bartonella quintana bacteremia is known to occur in homeless people exposed to lice. We present here the results of an open randomized trial performed to evaluate the efficacy of doxycycline in combination with gentamicin in the eradication of B. quintana bacteremia. From 1 January 2001 to 1 April 2002, homeless people with blood cultures positive for B. quintana were randomized to receive either no treatment (untreated controls) or a combination of gentamicin (3 mg/kg of body weight/day intravenously for 14 days) and doxycycline (200 mg/day orally for 28 days). Patients were evaluated from the results of blood cultures performed between day 28 (the end of treatment) and day 90 postinclusion. Intention-to-treat analysis of 20 included patients showed eradication of bacteremia in 7 out of 9 treated patients versus 2 out of 11 untreated controls (P = 0.01). In the per-protocol analysis, eradication was obtained for 7 out of 7 treated patients versus 2 out of 9 untreated controls (P = 0.003). This study demonstrates the efficiency of the combination of doxycycline and gentamicin in eradicating B. quintana bacteremia.

APA, Harvard, Vancouver, ISO, and other styles

4

Tarshis, Gary A., Barry M. Miskin, Terry M. Jones, John Champlin, Kevin J. Wingert, Jeanne D. Breen, and Michael J. Brown. "Once-Daily Oral Gatifloxacin versus Oral Levofloxacin in Treatment of Uncomplicated Skin and Soft Tissue Infections: Double-Blind, Multicenter, Randomized Study." Antimicrobial Agents and Chemotherapy 45, no. 8 (August 1, 2001): 2358–62. http://dx.doi.org/10.1128/aac.45.8.2358-2362.2001.

Full text

Abstract:

ABSTRACT This was a double-blind, multicenter study in which 410 adults (≥18 years of age) with uncomplicated skin and soft tissue infections (SSTIs) were randomized to receive either 400 mg of gatifloxacin orally once daily or 500 mg of levofloxacin orally once daily for 7 to 10 days. The study protocol called for four assessments—before and during treatment, at the end of treatment, and posttreatment. Efficacy evaluations included clinical response and bacterial eradication rates. Of 407 treated patients, 202 (108 women, 94 men) received gatifloxacin and 205 (111 women, 94 men) received levofloxacin. For clinically evaluable patients, the cure rates were 91% for gatifloxacin and 84% for levofloxacin (95% confidence interval [CI] for the difference, −2.0 to 15.2%). Clinical cure rates for microbiologically evaluable patients were 93% for gatifloxacin and 88% for levofloxacin (95% CI for the difference, −6.5 to 16.8%). The bacterial eradication rate was 92% for each group, with gatifloxacin eradicating 93% of the methicillin-susceptible Staphylococcus aureus isolates and levofloxacin eradicating 91% of them. Both drugs were well tolerated. Most of the adverse events were mild to moderate, and nausea was the most common adverse event in each treatment arm. Once-daily oral gatifloxacin (400 mg) is clinically efficacious and well tolerated compared with once-daily levofloxacin (500 mg) for the treatment of patients with uncomplicated SSTIs.

APA, Harvard, Vancouver, ISO, and other styles

5

Hopkins, Donald R., P. Craig Withers,, Robert L. Kaiser, Andrew N. Agle, and Ernesto Ruiz-Tiben. "Dracunculiasis Eradication: Beginning of the End." American Journal of Tropical Medicine and Hygiene 49, no. 3 (September 1, 1993): 281–89. http://dx.doi.org/10.4269/ajtmh.1993.49.281.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Butcher, James. "Polio eradication nears the end game." Lancet Neurology 7, no. 4 (April 2008): 292–93. http://dx.doi.org/10.1016/s1474-4422(08)70053-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Abraham, T. "Polio eradication: a complex end game." BMJ 344, apr02 2 (April 2, 2012): e2398-e2398. http://dx.doi.org/10.1136/bmj.e2398.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

John, T. J. "Polio eradication: End game and beyond." International Journal of Infectious Diseases 45 (April 2016): 27–28. http://dx.doi.org/10.1016/j.ijid.2016.02.094.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Hajiani, Eskandar, Pezhman Alavinejad, Nahid Avandi, Abdol Rahim Masjedizadeh, and Ali Akbar Shayesteh. "Comparison of Levofloxacin-Based, 10-day Sequential Therapy with 14-day Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial." Middle East Journal of Digestive Diseases 10, no. 4 (September 6, 2018): 242–48. http://dx.doi.org/10.15171/mejdd.2018.117.

Full text

Abstract:

BACKGROUND Considering the importance of Helicobacter pylori (H. pylori) eradication, this clinical trial was designed to prospectively evaluate the efficacy of levofloxacin-based, sequential therapy in comparison with quadruple therapy for eradicating H. pylori. METHODS Overall 156 patients with dyspepsia and H. pylori infection were included in this study and were randomly allocated to either 10-day sequential therapy group (group A) to receive pantoprazole (40 mg twice daily), amoxicillin (1 gr twice daily), levofloxacin (500 mg twice daily), and tinidazole (500 mg twice daily) (PALT) or 14-day quadruple therapy group (group B) to receive pantoprazole, clarithromycin, bismuth subcitrate, and amoxicillin (PABC). At the end of the study the eradication rate in each group was assessed by urea breath test (UBT). RESULTS Age range of the participants was 18-65 years (average 36.9 years) and 50% of them (78 patients) were men. 78 patients were allocated to group A and 78 patients to groupe B. After antibiotic therapy, all the patients received acid suppression therapy with Proton Pump Inhibitor (PPI) for 4 weeks and then the eradication rate was confirmed by UBT (Heli FAN plus 13C, Germany). Before performing UBT, all the participants were requested to halt consumption of PPI for at least 1 week. During the treatment there was not any major complication but in group A (sequential therapy), two patients complained of minor complications including musculoskeletal pain. None of the patients in group B had any complaint or side effect. The rate of H. pylori eradication in group A was 78.2% (61 patients) while this rate in group B was 83.3% (65 patients) with no significant difference between the two groups (p = 0.42). In subgroup analysis, the rate of eradication among men in group A and B were 76.9% and 89.7%, respectively (p = 0.22) while the eradication rate among women were 79.4% and 76.9%, respectively (p = 1.00). CONCLUSION It seems that levofloxacin base sequential therapy does not have any advantage in comparison with quadruple regimen and until finding any more effective short course therapy for H. Pylori eradication; we encourage quadruple regimen to be used as the first line therapy.

APA, Harvard, Vancouver, ISO, and other styles

10

Biswas, Gautam, Dieudonne P. Sankara, Junerlyn Agua-Agum, and Alhousseini Maiga. "Dracunculiasis (guinea worm disease): eradication without a drug or a vaccine." Philosophical Transactions of the Royal Society B: Biological Sciences 368, no. 1623 (August 5, 2013): 20120146. http://dx.doi.org/10.1098/rstb.2012.0146.

Full text

Abstract:

Dracunculiasis, commonly known as guinea worm disease, is a nematode infection transmitted to humans exclusively via contaminated drinking water. The disease prevails in the most deprived areas of the world. No vaccine or medicine is available against the disease: eradication is being achieved by implementing preventive measures. These include behavioural change in patients and communities—such as self-reporting suspected cases to health workers or volunteers, filtering drinking water and accessing water from improved sources and preventing infected individuals from wading or swimming in drinking-water sources—supplemented by active surveillance and case containment, vector control and provision of improved water sources. Efforts to eradicate dracunculiasis began in the early 1980s. By the end of 2012, the disease had reached its lowest levels ever. This paper reviews the progress made in eradicating dracunculiasis since the eradication campaign began, the factors influencing progress and the difficulties in controlling the pathogen that requires behavioural change, especially when the threat becomes rare. The challenges of intensifying surveillance are discussed, particularly in insecure areas containing the last foci of the disease. It also summarizes the broader benefits uniquely linked to interventions against dracunculiasis.

APA, Harvard, Vancouver, ISO, and other styles

11

Eisig, Jaime Natan, Suraia Boaventura André, Fernando Marcuz Silva, Cláudio Hashimoto, Joaquim Prado Pinto Moraes-Filho, and Antonio Atilio Laudanna. "The impact of Helicobacter pylori resistance on the efficacy of a short course pantoprazole based triple therapy." Arquivos de Gastroenterologia 40, no. 1 (March 2003): 55–60. http://dx.doi.org/10.1590/s0004-28032003000100012.

Full text

Abstract:

BACKGROUND: Many of the currently used Helicobacter pylori eradication regimens fail to cure the infection due to either antimicrobial resistance or poor patient compliance. Those patients will remain at risk of developing potentially severe complications of peptic ulcer disease. AIM: We studied the impact of the antimicrobial resistance on the efficacy of a short course pantoprazole based triple therapy in a single-center pilot study. METHODS: Forty previously untreated adult patients (age range 20 to 75 years, 14 males) infected with Helicobacter pylori and with inactive or healing duodenal ulcer disease were assigned in this open cohort study to 1 week twice daily treatment with pantoprazole 40 mg, plus clarithromycin 250 mg and metronidazole 400 mg. Helicobacter pylori was assessed at entry and 50 ± 3 days after the end of treatment by rapid urease test, culture and histology of gastric biopsies. The criteria for eradication was a negative result in the tests. Susceptibility of Helicobacter pylori to clarithromycin and metronidazole was determined before treatment with the disk diffusion test. RESULTS: One week treatment and follow up were complete in all patients. Eradication of Helicobacter pylori was achieved in 35/40 patients (87.5%) and was higher in patients with nitroimidazole-susceptible strains [susceptible: 20/20 (100%), resistant: 10/15 (67%)]. There were six (15%) mild adverse events reports. CONCLUSIONS: A short course of pantoprazole-based triple therapy is well tolerated and effective in eradicating Helicobacter pylori. The baseline metronidazole resistance may be a significant limiting factor in treatment success.

APA, Harvard, Vancouver, ISO, and other styles

12

The Lancet Neurology. "Polio eradication: the beginning of the end." Lancet Neurology 3, no. 7 (July 2004): 383. http://dx.doi.org/10.1016/s1474-4422(04)00789-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Schwarzkopf, Ran, Daniel Oh, Elizabeth Wright, Daniel M. Estok, and Jeffery N. Katz. "Treatment Failure Among Infected Periprosthetic Patients at a Highly Specialized Revision TKA Referral Practice." Open Orthopaedics Journal 7, no. 1 (June 28, 2013): 264–71. http://dx.doi.org/10.2174/1874325001307010264.

Full text

Abstract:

Deep infection is a serious and costly complication of total knee arthroplasty (TKA), which can increase patient morbidity and compromise functional outcome and satisfaction. Two-stage revision with an interval of parental antibiotics has been shown to be the most successful treatment in eradicating deep infection following TKA. We report a large series by a single surgeon with a highly specialized revision TKA referral practice. We identified 84 patients treated by a two-stage revision. We defined “successful two-stage revision” as negative intraoperative cultures and no further infection-related procedure. We defined “eradication of infection” on the basis of negative cultures and clinical diagnosis. After a mean follow up of 25 months, eradication of the infection was documented in 90.5% of the patients; some had undergone further surgical intervention after the index two-stage procedure. Successful two-stage revision (e.g. no I&D, fusion, amputation) was documented only in 63.5% of the patients. We also observed a trend between presence of resistant staphylococcus (MRSA) (p=0.05) as well as pre-revision surgical procedures (p=0.08) and a lower likelihood of successfully two-stage revision. Factors affecting the high failure rate included multiple surgeries prior to the two-stage revision done at our institution, and high prevalence of MRSA present among failed cases. The relatively high rate of failure to achieve a successful two-stage revision observed in our series may be attributed to the highly specialized referral practice. Thus increasing the prevalence of patients with previous failed attempts at infection eradication and delayed care as well as more fragile and immune compromised hosts.

APA, Harvard, Vancouver, ISO, and other styles

14

Strati, Paolo, Michael J. Keating, Susan M. O'Brien, Jan Burger, Alessandra Ferrajoli, Nitin Jain, Francesco Paolo Tambaro, et al. "Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL." Blood 123, no. 24 (June 12, 2014): 3727–32. http://dx.doi.org/10.1182/blood-2013-11-538116.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Sutter, Roland W., Rudolf H. Tangermann, R. Bruce Aylward, and Stephen L. Cochi. "Poliomyelitis Eradication: Progress, Challenges for the End Game, and Preparation for the Post-Eradication Era." Infectious Disease Clinics of North America 15, no. 1 (March 2001): 41–64. http://dx.doi.org/10.1016/s0891-5520(05)70267-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Summerfield, Derek. "An End To Torture: Strategies for its Eradication." BMJ 318, no. 7194 (May 15, 1999): 1358.2. http://dx.doi.org/10.1136/bmj.318.7194.1358-b.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Shilbe, A. S., G. E. Yembo, D. J. Wayesa, A. B. Woyessa, T. B. Anbessie, A. K. Habtemichael, Z. Z. Kebede, and K. Haile. "Ethiopian dracunculiasis eradication, the end game challenges, 2015." International Journal of Infectious Diseases 45 (April 2016): 244. http://dx.doi.org/10.1016/j.ijid.2016.02.546.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Tucci, A., L. Poli, C. Mazzoni, G. F. Paparo, G. Caletti, P. Bocus, A. Ferrari, et al. "Week-end therapy for H. pylori (HP) eradication." Gastroenterology 108, no. 4 (April 1995): A246. http://dx.doi.org/10.1016/0016-5085(95)23645-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Muller, R. "Guineaworm eradication — the end of another old disease?" Parasitology Today 1, no. 2 (August 1985): 39–58. http://dx.doi.org/10.1016/0169-4758(85)90109-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Saint-Victor, Diane S., and Saad B. Omer. "Vaccine refusal and the endgame: walking the last mile first." Philosophical Transactions of the Royal Society B: Biological Sciences 368, no. 1623 (August 5, 2013): 20120148. http://dx.doi.org/10.1098/rstb.2012.0148.

Full text

Abstract:

As multiple papers within this special issue illustrate, the dynamics of disease eradication are different from disease control. When it comes to disease eradication, ‘the last mile is longest’. For social and ecological reasons such as vaccine refusal, further ending incidence of a disease when it has reached low levels is frequently complex. Issues of non-compliance within a target population often influence the outcome of disease eradication efforts. Past eradication efforts confronted such obstacles towards the tail end of the campaign, when disease incidence was lowest. This article provides a comparison of non-compliance within polio, measles and smallpox campaigns, demonstrating the tendency of vaccine refusal to rise as disease incidence falls. In order to overcome one of the most intractable challenges to eradication, future disease eradication efforts must prioritize vaccine refusal from the start, i.e. ‘walk the last mile first’.

APA, Harvard, Vancouver, ISO, and other styles

21

Khuri-Bulos, Najwa. "Polio eradication—rethinking the endpoint of the end game." Lancet Infectious Diseases 4, no. 5 (May 2004): 262–63. http://dx.doi.org/10.1016/s1473-3099(04)00999-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Summerfield, D. "Book: An End To Torture: Strategies for its Eradication." BMJ 318, no. 7194 (May 15, 1999): 1358. http://dx.doi.org/10.1136/bmj.318.7194.1358a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Wagner, Christopher. "An End to Torture: Strategies for its Eradication (review)." Human Rights Quarterly 22, no. 2 (2000): 630–34. http://dx.doi.org/10.1353/hrq.2000.0030.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Hillemanns, Peter. "Eradication of cervical cancer: the beginning of the end." Archives of Gynecology and Obstetrics 289, no. 3 (January 9, 2014): 477–78. http://dx.doi.org/10.1007/s00404-013-3127-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Peterson, Paul D. "The Barberry Eradication Program in Minnesota for Stem Rust Control: A Case Study." Annual Review of Phytopathology 56, no. 1 (August 25, 2018): 203–23. http://dx.doi.org/10.1146/annurev-phyto-080417-050133.

Full text

Abstract:

The Barberry Eradication Program was an unprecedented federal and state cooperative plant disease control campaign between 1918 and the late 1970s to remove common barberry ( Berberis vulgaris), the alternate host of Puccinia graminis f. sp. tritici, from the major centers of wheat production in the United States. Eradication of barberry has been credited with helping to reduce stem rust of wheat to a minor problem in the United States by the end of the campaign. The Barberry Eradication Program has also been viewed as a model for successful eradication based on its robust leadership, effective publicity and public cooperation, forceful quarantine laws, and adaptive eradication methods and procedures employed in its field operations. The Barberry Eradication Program was particularly successful because of its leaders’ ability to adapt to changing internal and external conditions over time. The program lasted nearly a century, extending through two world wars and the Great Depression, with each period producing unique challenges. Because of its central role, barberry eradication in Minnesota offers an excellent case study to examine how the program developed over time and ultimately achieved success.

APA, Harvard, Vancouver, ISO, and other styles

26

Dekhnich, N. N., N. V. Ivanchik, E. A. Prischepova, and R. S. Kozlov. "THE CHOOSE HELICOBACTER PYLORI ERADICATION THERAPY IN ADULTS." Experimental and Clinical Gastroenterology 148, no. 12 (December 2017): 60–66. http://dx.doi.org/10.31146/1682-8658-ecg-148-12-60-66.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Johnston, Gregory R. "Drought increases the impact of introduced European foxes on breeding Australian pelicans." Wildlife Research 43, no. 6 (2016): 507. http://dx.doi.org/10.1071/wr15207.

Full text

Abstract:

Context Introduced mammalian predators have been responsible for population declines in native prey species around the world. Many conservation programs rely on control or eradication of introduced mammalian predators, but the impact of environmental variation on the efficacy of this approach is rarely documented. Aims The present paper describes (1) the impact of introduced European foxes (Vulpes vulpes) on breeding Australian pelicans (Pelecanus conspicillatus) in South Australia and (2) the responses of both species to a fox-eradication program using a before-after-impact framework. Methods The impact of foxes on breeding Australian pelicans was studied on a near-shore island. An index of fox abundance and direct measurements of breeding pelicans and mortality of pelican eggs and young were compared before foxes were established on the island, while foxes were resident and during a fox-eradication program. A path analysis was used to explore the causal relationships between fox abundance and other potential covariates (e.g. rainfall) on breeding pelicans. Key results Before foxes were established on the island, the number of breeding pelicans grew and egg mortality was low. While foxes were resident, the number of breeding pelicans fell and egg mortality rose. This was followed by an increase in the number of breeding pelicans and a decrease in egg mortality during a fox-eradication program. While foxes had a clear impact on egg mortality, a period of low rainfall also occurred while foxes were resident. The path analysis showed an interaction among rainfall, size of the pelican breeding population and the impact of foxes. In drought years, fewer pelicans bred and foxes were a major cause of nest abandonment when they entered pelican breeding colonies to prey on eggs. Conclusions These results confirmed that foxes can be an important predator of ground-nesting, colonial waterbirds, and showed that the impact of foxes may be higher in drought years when prey populations are low. Implications The present study suggests that an increase in the incidence of droughts as a result of climate change may increase the impact of introduced predators on drought-sensitive waterbirds and raises the possibility of focussing predator-control efforts during droughts, as periods of particular risk to colony-breeding waterbirds.

APA, Harvard, Vancouver, ISO, and other styles

28

Minor, Philip D. "The polio-eradication programme and issues of the end game." Journal of General Virology 93, no. 3 (March 1, 2012): 457–74. http://dx.doi.org/10.1099/vir.0.036988-0.

Full text

Abstract:

Poliovirus causes paralytic poliomyelitis, an ancient disease of humans that became a major public-health issue in the 20th century. The primary site of infection is the gut, where virus replication is entirely harmless; the two very effective vaccines developed in the 1950s (oral polio vaccine, or OPV, and inactivated polio vaccine, or IPV) induce humoral immunity, which prevents viraemic spread and disease. The success of vaccination in middle-income and developing countries encouraged the World Health Organization to commit itself to an eradication programme, which has made great advances. The features of the infection, including its largely silent nature and the ability of the live vaccine (OPV) to evolve and change in vaccine recipients and their contacts, make eradication particularly challenging. Understanding the pathogenesis and virology of the infection is of major significance as the programme reaches its conclusion.

APA, Harvard, Vancouver, ISO, and other styles

29

Kao, Sung-Shuo, Wen-Chi Chen, Ping-I. Hsu, Kwok-Hung Lai, Hsien-Chung Yu, Hui-Hwa Cheng, Nan-Jing Peng, et al. "7-Day Nonbismuth-Containing Concomitant Therapy Achieves a High Eradication Rate forHelicobacter pyloriin Taiwan." Gastroenterology Research and Practice 2012 (2012): 1–6. http://dx.doi.org/10.1155/2012/463985.

Full text

Abstract:

Background.Ten-day concomitant therapy achieves a high eradication rate in Taiwan. Whether shortening the duration of concomitant therapy can still keep a high eradication rate remains unclear.Aim.To assess the eradication rate of 7-day pantoprazole-containing concomitant therapy in Taiwan and to investigate factors influencing the eradication outcome.Methods.From March 2008 to March 2012, 319H. pylori-infected patients receiving a 7-day pantoprazole-containing concomitant regimen (pantoprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg twice daily for 7 days) were included. Patients were asked to return at the second week to assess drug compliance and adverse effects. Repeated endoscopy or urea breath test was performed at 8 weeks after the end of eradication therapy.Results.The eradication rates according to intention-to-treat and per-protocol analyses were 93.7% (299/319) and 96.4% (297/308), respectively. Adverse events occurred in 13.2% (42/319) of the patients. The compliance rate was 98.4% (314/319). Multivariate analysis disclosed that poor compliance was the only independent factor influencing the efficacy of anti-H. pyloritherapy with an odds ratio of 0.073 (95% confidence interval, 0.011–0.483).Conclusion.7-day concomitant therapy achieved a very high eradication rate forH. pyloriinfection in Taiwan. Drug compliance was the only clinical factor influencing treatment efficacy.

APA, Harvard, Vancouver, ISO, and other styles

30

Paul, Yash. "Polio eradication in India: Have we reached the dead end?" Vaccine 28, no. 7 (February 2010): 1661–62. http://dx.doi.org/10.1016/j.vaccine.2009.11.084.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

MATIC, STJEPAN, VLADO MIHOKOVIC, BRANKA KATUSIN-RAZEM, and DUSAN RAZEM. "The Eradication of Salmonella in Egg Powder by Gamma Irradiation." Journal of Food Protection 53, no. 2 (February 1, 1990): 111–14. http://dx.doi.org/10.4315/0362-028x-53.2.111.

Full text

Abstract:

The contamination of whole egg powder with salmonellae was investigated in suspected samples. They were found to contain between 0.1 and 0.01 CFU/g of S. lille, S. enteritidis, and S. typhimurium. The radiation resistance of these strains was investigated in artificially inoculated whole egg powder. The decimal reduction dose (D10) 0.8 kGy was obtained for a mixture of the three strains. A reduction factor of 103 can therefore be accomplished by irradiation with 2.4 kGy. While this may be adequate in many cases, higher reduction factors may also be desirable. They are obviously possible with a higher dose of radiation, or, alternatively, by following low-dose irradiation with post-irradiation storage. For example, irradiation with 1 kGy followed by 3 weeks' storage is approximately equivalent to the immediate bactericidal effect of 3 kGy.

APA, Harvard, Vancouver, ISO, and other styles

32

Sutter, R. W., L. Platt, O. Mach, H. Jafari, and R. B. Aylward. "The New Polio Eradication End Game: Rationale and Supporting Evidence." Journal of Infectious Diseases 210, suppl 1 (October 14, 2014): S434—S438. http://dx.doi.org/10.1093/infdis/jiu222.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Rodríguez-Álvarez, Mauricio, María Eugenia Jiménez-Corona, Rocío Cervantes-Rosales, and Samuel Ponce de León-Rosales. "Polio Eradication: How Long and How Much to the End?" Archives of Medical Research 44, no. 5 (July 2013): 401–4. http://dx.doi.org/10.1016/j.arcmed.2013.05.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Prikhodko, M. N., Zh G. Simonova, and E. P. Kolevatykh. "Guality eradication anti-helicobacter therapy increases the effectiveness of treatment of patients with stable angina pectoris." Experimental and Clinical Gastroenterology, no. 2 (April 7, 2021): 41–46. http://dx.doi.org/10.31146/1682-8658-ecg-186-2-41-46.

Full text

Abstract:

Aim. On the basis of the complex analysis, to evaluate the efficiency of eradication therapy at patients with stable stenocardia with a combination of chronic gastritis. Material and methods. 46 patients with stable stenocardia with a combination of chronic H. pylori-associated gastritis were included in the open prospective clinical study. Two groups of patients were formed during the study. Patients of group I (n = 25) received eradication therapy in accordance with antibiotic sensitivity of H. pylori strains, patients of group II (n = 21) - without antibiotic sensitivity. In all patients before and after treatment were performed: evaluation of clinical status, laboratory indicators, EGDS with biopsy sampling, diagnosis of H. pylori. Results. The effectiveness of eradication therapy was 86.9%, at the same time, 96% -in group I and 76.2% - in group II. It is established: stabilization of clinical status of patients, improvement of morphological and endoscopic picture of gastroduodenal zone, improvement of laboratory indices. Conclusions. The inclusion of antibiotic-sensitive erication therapy in the algorithm of treatment of patients with stable stenocardia in combination with chronic gastritis allows to achieve high effectiveness of killing the infection Helicobacter pylori. At the same time stabilizes clinical status of patients, laboratory indices, has a positive effect on morphological and endoscopic picture of gastroduodenal zone, preventing progression of metaplastic changes.

APA, Harvard, Vancouver, ISO, and other styles

35

Fisher, Campbell, Howald, and Warburton. "Anticoagulant Rodenticides, Islands and Animal Welfare Accountancy." Animals 9, no. 11 (November 4, 2019): 919. http://dx.doi.org/10.3390/ani9110919.

Full text

Abstract:

Anticoagulant rodenticides are used to manage rodents in domestic, municipal, agricultural, and conservation settings. In mammals and birds, anticoagulant poisoning causes extensive hemorrhagic disruption, with the primary cause of death being severe internal bleeding occurring over days. The combined severity and duration of these effects represent poor welfare outcomes for poisoned animals. Noting a lack of formal estimates of numbers of rodents and nontarget animals killed by anticoagulant poisoning, the ready availability and worldwide use of anticoagulants suggest that very large numbers of animals are affected globally. Scrutiny of this rodent control method from scientific, public, and regulatory perspectives is being driven largely by mounting evidence of environmental transfer of residual anticoagulants resulting in harmful exposure in wild or domestic animals, but there is also nascent concern for the welfare of targeted rodents. Rodent control incurs a cumulative ledger of animal welfare costs over time as target populations reduced by poisoning eventually recover to an extent requiring another reduction. This ‘rolling toll’ presents a critical contrast to the animal welfare accountancy ledger for eradication scenarios, where rodent populations can be completely removed by methods including anticoagulant use and then kept from coming back (e.g., on islands). Successful eradications remove any future need to control rodents and to incur the associated animal welfare costs.

APA, Harvard, Vancouver, ISO, and other styles

36

Tjan, Richard. "2015: The beginning of the end of the war against malaria." Universa Medicina 34, no. 2 (December 15, 2015): 77. http://dx.doi.org/10.18051/univmed.2015.v34.77-78.

Full text

Abstract:

In May 2015 the 62th World Health Assembly formulated a global malaria strategy for 2016-2030 aiming to “reduce the global disease burden by 40% by 2020, and by at least 90% by 2030. It also aims to eliminate malaria in at least 35 new countries by 2030”.(1) As a reminder, it was 60 years ago that the Eighth World Health Assembly decided in 1955 to shift from malaria control to malaria eradication, with the aim to make many areas of free of malaria “within 10 to 15 years”.(2) This has yet to be accomplished in many malaria endemic countries such as Indonesia, where the earliest program was the malaria eradication program of 1959, evolving into the malaria control program, the roll-back malaria program, and finally in 2012 into the malaria elimination program.(3) In view of the ever-present insecticideresistance

APA, Harvard, Vancouver, ISO, and other styles

37

Harbarth, Stephan, Sasi Dharan, Nadia Liassine, Pascale Herrault, Raymond Auckenthaler, and Didier Pittet. "Randomized, Placebo-Controlled, Double-Blind Trial To Evaluate the Efficacy of Mupirocin for Eradicating Carriage of Methicillin-Resistant Staphylococcus aureus." Antimicrobial Agents and Chemotherapy 43, no. 6 (June 1, 1999): 1412–16. http://dx.doi.org/10.1128/aac.43.6.1412.

Full text

Abstract:

ABSTRACT Mupirocin has been widely used for the clearance of nasal methicillin-resistant Staphylococcus aureus (MRSA) carriage during outbreaks, but no placebo-controlled trial has evaluated its value for eradicating MRSA carriage at multiple body sites in settings where MRSA is not epidemic. In a 1,500-bed teaching hospital with endemic MRSA, 102 patients colonized with MRSA were randomized into a double-blind, placebo-controlled trial and treated with either mupirocin (group M) or placebo (group P) applied to the anterior nares for 5 days; both groups used chlorhexidine soap for body washing. Follow-up screening, susceptibility testing, and genotyping were performed to evaluate treatment success, mupirocin or chlorhexidine resistance, and exogenous recolonization. At baseline, MRSA carriage was 60% in the nares, 38% in the groin, and 62% in other sites (skin lesions, urine). The MRSA eradication rate (all body sites) was 25% in group M (12 of 48 patients), compared to 18% in group P (9 of 50 patients; relative risk [RR], 0.72; 95% confidence interval [CI95], 0.33 to 1.55). At the end of follow-up, 44% of patients (19 of 43) were free of nasal MRSA in group M, compared to 23% (11 of 44) in group P (RR, 0.57; CI95, 0.31 to 1.04). Ten patients developed MRSA infections (three in group M and seven in group P). One mupirocin treatment failure was due to exogenous MRSA recolonization. No MRSA isolate showed chlorhexidine resistance or high-level mupirocin resistance; however, we observed an association (P = 0.003) between low-level mupirocin resistance at study entry (prevalence, 23%) and subsequent treatment failure in both study arms. These results suggest that nasal mupirocin is only marginally effective in the eradication of multisite MRSA carriage in a setting where MRSA is endemic.

APA, Harvard, Vancouver, ISO, and other styles

38

Razavizadeh, Mohsen, Abbas Arj, Maryam Madani, and Hamidreza Gilassi. "Comparing the Efficacy of Sequential and Standard Quadruple Therapy for Eradication of H. Pylori Infection." Acta Medica (Hradec Kralove, Czech Republic) 63, no. 4 (2020): 183–87. http://dx.doi.org/10.14712/18059694.2020.61.

Full text

Abstract:

Background: The aim of this study was comparison the effectiveness of sequential and standard quadruple therapy on eradication of H. pylori infection. Methods: This clinical trial study was conducted on 160 patients with dyspepsia or gastroduodenal ulcer. Patients were randomly divided into two groups. Group A (standard regimen) received omeprazole, amoxicillin, clarithromycin and bismuth subcitrate for 2 weeks. Group B (sequential regimen) received omeprazole and amoxicillin in 5 days and omeprazole, tinidazole and levofloxacin in 5 days. After the end of treatment regimens, 20 mg omeprazole was administered twice daily for 3 weeks. H. pylori eradication was assessed 2 months after antibiotic treatment via fecal antigen. Results: Frequency of H. pylori eradication in group A and B was observed in 55 (68.8%) and 63 patients (78.8%), respectively. No significant difference was seen between two groups, regarding H. pylori eradication (p = 0.15). The most common side effects in group A, B were bitterness of mouth (63.8%) and nausea (16.2%), respectively (p < 0.001). Conclusion: Although no significant difference was seen between two groups regarding eradication of H. pylori infection, higher rate of H. pylori eradication was seen in group B than group A. Thus, sequential regimen was a more appropriate regimen with fewer complications.

APA, Harvard, Vancouver, ISO, and other styles

39

Ahn, Hyo Jun, Dong Pil Kim, Myeong Su Chu, Hyeon Jeong Yun, Seok-Hwan Kim, Seung Woo Lee, and Dong Soo Lee. "Efficacy and Safety of the Triple Therapy Containing Ilaprazole, Levofloxacin, and Amoxicillin as First-Line Treatment in Helicobacter pylori Infections." Gastroenterology Research and Practice 2017 (2017): 1–6. http://dx.doi.org/10.1155/2017/1654907.

Full text

Abstract:

Background and Aims. To establish the efficacy and safety of ilaprazole, levofloxacin, and amoxicillin as a first-line eradication treatment for Helicobacter pylori. Methods. Patients with gastric ulcer, duodenal ulcer, or gastritis, as detected by esophagogastroduodenoscopy with confirmed H. pylori infection between September 2014 and November 2015, were enrolled in the study. All participants received ilaprazole (10 mg bid), levofloxacin (500 mg bid), and amoxicillin (1000 mg bid) for 10 days. H. pylori eradication was confirmed by a 13C-urea breath test at 6–8 weeks after the end of treatment. Results. Of 84 patients included in the analysis, the eradication rate was 88.8% in the per protocol group (n=80). Demographic factors such as age, gender, body mass index (BMI), alcohol, smoking, hypertension, diabetes mellitus, and peptic ulcer did not affect the eradication rate. However, multivariate analysis showed that overweight patients and patients with cerebrovascular accident (CVA) had a significantly lower eradication rate than patients with normal BMI and without CVA. Laboratory test results did not change significantly after treatment. A total of six (7.5%) patients developed eight adverse reactions. Conclusions. A 10-day triple therapy containing ilaprazole, levofloxacin, and amoxicillin is a safe alternative first-line eradication treatment for H. pylori.

APA, Harvard, Vancouver, ISO, and other styles

40

Nam, Seung-Hyun, Bong-Seog Kim, Jae Hoon Lee, Hong Suk Song, Sung-Hwa Bae, Myung Soo Hyun, Young Jin Yuh, Sang-Jae Lee, and Seonyang Park. "The Clinical Efficacy of Helicobacter pylori Eradication in Patients with Helicobacter pylori-Positive Chronic Thrombocytopenic Purpura." Blood 106, no. 11 (November 16, 2005): 4002. http://dx.doi.org/10.1182/blood.v106.11.4002.4002.

Full text

Abstract:

Abstract Background: Helicobacter pylori (H pylori) has been implicated in the pathogenesis of some autoimmune diseases including idiopathic thrombocytopenic purpura (ITP). Several studies recently showed a high prevalence of H pylori infection in patients with ITP and reported a platelet recovery after bacterial eradication therapy. The prevalence of H pylori infection and effect of its eradication in Korea patients with chronic ITP were investigated. Methods: The study included among 35 patients with chronic ITP from eight hospitals. H pylori infection was assessed by urea breath test, rapid urease test or microbial culture. H pylori eradication was performed with amoxicillin, clarithromycin and omeprazol regimen for 7 days or bismuth, metronidazol and tetracycline regimen for 10 days. Eradication was assessed by urea breath test 4 weeks after treatment. Platelet counts were monitored serially after the end of treatment. Results: Thirty five patients with chronic ITP were evaluated, including 12 males and 23 females. Median age was 57 years (range 30–79). The median platelet count before eradication was 23,000/uL (range 4,000–66,000/uL). Sixteen patients were performed the splenectomy previously. H pylori infection was found in 23 (65%) of 35 patients. In 21 patients performed the eradication, 6 patients (28.5%) had a significant increase in platelet count after 2 weeks and 2 months. The response duration was 1–27 (median 7.6) months. Conclusions: This study confirmed the efficacy of H pylori eradication in increasing platelet in adult chronic ITP patients. We must consider the investigation and eradication of H pylori infection in ITP patients as a simple, inexpensive tool in management of the chronic disease.

APA, Harvard, Vancouver, ISO, and other styles

41

Sarsenbaevа, A. S., and E. V. Domracheva. "Differentiated approach to eradication therapy in patients with chronic pancreatitis." Experimental and Clinical Gastroenterology, no. 6 (August 4, 2020): 64–70. http://dx.doi.org/10.31146/1682-8658-ecg-178-6-64-70.

Full text

Abstract:

Purpose of the study. Compare the effectiveness of different eradication therapy regimens in patients with chronic pancreatitis with concomitant gastritis associated with various genetic variants of H. pylori.Materials and methods: 63 patients with chronic pancreatitis and concomitant Helicobacter pylori-associated gastritis were examined. The control group consisted of 45 patients with chronic gastritis. Diagnosis of chronic pancreatitis was based on anamnestic, clinical data, instrumental studies (MSCT). Diagnosis of H. pylori infection was carried out by the morphological method, 13C urease breath test, and immunoblotting. Statistical processing was carried out using application packages SPSS Statistic 17.0.Results. In patients with chronic pancreatitis, CagA-positive H. pylori strains were found 19.3% less often compared with the control group (p <0.05), VacA-positive—21.9% less often (p <0.05). In the study group, H. pylori genes encoding urease A production and genes encoding the synthesis of H. pylori outer membrane proteins (p33, p30, p29, p26, p19, p17) were significantly more frequently met. In the group of patients with chronic pancreatitis, the standard triple therapy of the 1st line with the inclusion of bismuth tripotassium dicitrate was 86.8% more effective (p <0.01) compared to the standard triple therapy of the 1st line, and the maximum increase in efficiency was observed among owners of H. pylori strains, expressing urease A and with the representation on the outer membrane of the proteins p30, p33, p26, p19, p17 (p <0.01).Conclusion. Eradication therapy in patients with chronic pancreatitis in the presence of pathogenicity complex p30, p33, urease A, p26, p19, p17 in H. pylori according to the standard line triple therapy protocol with the inclusion of bismuth tripotassium dicitrate has advantages compared to the standard triple therapy protocol 1 line (p <0.001).

APA, Harvard, Vancouver, ISO, and other styles

42

Bridger, Stephen. "H. pylori eradication: end of the road for PPI triple therapy?" Prescriber 19, no. 8 (2008): 7–8. http://dx.doi.org/10.1002/psb.225.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Luzina, E. V., L. B. Lazebnik, N. V. Lareva, N. N. Chartorizhskaya, A. A. Dutova, V. V. Melnikov, and T. B. Mutsolgova. "Experience of Chita the program of the Scientific Society of Gastroenterologists of Russia and Russian Scientific Medical Society of Internal Medicine “Physicians without helicobacteriosis”." Experimental and Clinical Gastroenterology, no. 3 (June 22, 2020): 34–46. http://dx.doi.org/10.31146/1682-8658-ecg-175-3-34-46.

Full text

Abstract:

Objective. To determine the prevalence of Helicobacter pylori (HP) in doctors in Chita, to identify clinical manifestations of infection, endoscopic, ultrasound and morphological changes in the stomach, to conduct eradication treatment with an assessment of its effectiveness, to determine the resistance of HP to clarithromycin and to develop treatment tactics for HP-associated diseases in the region.Material and methods. 70 doctors of Chita were examined, including 55 women and 15 men, average age 47.04±12.76 years (20 persons were 39 years and younger, 33 persons were 40–59 years, 17 people were 60 years and older; 27 persons were gastroenterologists, 17 — therapists, 11 — pediatricians, 5 — surgeons and 10 persons were doctors of other specialties). All doctors underwent antigen (AH) of HP determination in feces, a survey on the original questionnaire to assess clinical manifestations. Ultrasound examination of the stomach was performed in 47 doctors. Endoscopy of the upper gastrointestinal tract (GI) was performed in 35 persons. During endoscopy, in 29 doctors biopsy material of the mucous membrane from 5 points of the stomach were taken. A histological examination of biopsy samples was performed with an assessment using the OLGA system. The resistance of HP to clarithromycin was determined by the molecular genetic method in biopsy samples of gastric biopsy. 44 doctors conducted eradication with different schemes. Adverse events (AE) and treatment tolerance were evaluated. Control of eradication was carried out 6–8 weeks after the end of therapy by determining AH of HP in the feces. Statistical processing was carried out using the method of descriptive statistics, criterion of Student and criterion x2 (Biostatprogramm).Results. A positive AH of HP in feces was registered in 71.4% of the doctors examined: 73.3% of men and 70.9% of women, 75% of people under the age of 39 years, 72.7% of those aged 40–59 years and 64.7% are over 60 years old. Gastroenterologists were infected in 63%, therapists in 70.6%, pediatricians in 72.7%, surgeons in 80%, another specialists in 90% of cases. In the presence of HP, 81.6% of the examined showed symptoms from the digestive organs, 3 times more often a hereditary history of stomach cancer was determined. The wall thickness of the stomach during ultrasound in the infected was recorded 0.21–0.18 mm more than in the group of HP-negative individuals. A histological examination of III–IV degree of activity of inflammation in the stomach was diagnosed in 86.1%, stage III atrophy and colonic metaplasia in 20.7% of the examined doctors. The desire to conduct eradication treatment was expressed by 78% of doctors, 44 people completed the therapy. Non-compliance with the eradication regimen was noted in 9 people. AE were registered in 76.6% of cases. The efficacy of all regimens was 71.4%: when using the regimen with clarithromycin — 73%, with josamycin — 100%, with tetracycline and metronidazole — 33%, with levofloxacin — 100%. HP DNA was detected in 27 samples of gastric. In 10 cases, mutations A2142G and A2143G in the HP genome were detected, providing resistance to clarithromycin, which amounted to 37%.Conclusion1. 71.4% of doctors in Chita are infected with HP, among which the bacterium is most often detected at a young age (39 years and younger).2. Infected doctors are more likely to have gastrointestinal symptoms, a history of gastric damage, and hereditary gastric cancer.3. In 20.7% of doctors, histological examination revealed colonic metaplasia and dysplasia, which confirms the need for treatment and requires further observation.4. Only 78% of Chita doctors expressed their readiness to eradicate HP, and 20.4% of those who started treatment did not comply with the treatment regimen. This fact requires further educational activities.5. The efficacy of eradication by all schemes was 71.4%. Genotypic resistance of HP to clarithromycin was found in 37% of doctors. Further studies are needed to identify the characteristics of the macro- and microorganism (genetic polymorphism of enzymes, HP mutations) in groups, both among doctors and other categories of patients who do not have professional contacts with microorganisms and antibiotics in order to develop recommendations on the use of HP eradication schemes in region.

APA, Harvard, Vancouver, ISO, and other styles

44

Tepes, Bojan, Marko Kastelic, Miroslav Vujasinovic, Polona Lampic, Maja Seruga, Natasa Brglez Jurecic, Olga P. Nyssen, et al. "Helicobacter pylori treatment results in Slovenia in the period 2013-2015 as a part of European Registry on Helicobacter pylori Management." Radiology and Oncology 52, no. 1 (December 7, 2017): 1–6. http://dx.doi.org/10.1515/raon-2017-0055.

Full text

Abstract:

Abstract Background Helicobacter pylori (H. pylori) is the most common chronic bacterial infection in the world affecting over 50% of the world’s population. H. pylori is a grade I carcinogen, responsible for the development of 89 % of noncardia gastric cancers. In the present study we analyzed the data for H. pylori eradication treatments in Slovenia. Patients and methods Slovenia is a part of the European Registry on Helicobacter pylori Management from the beginning. In seven medical institutions data for H. pylori eradication treatments was collected for 1774 patients from April 16th 2013 to May 15th 2016. For further modified intention to treat (mITT) analysis 1519 patients were eligible and for per protocol (PP) analysis 1346 patients. Results Patients’ dropout was 11.4%. Eradication rate for 7 day triple therapy with proton pump inhibitor (PPI) + Clarithromycin (C) + Amoxicillin (A) was 88.7% PP and 72.0% mITT; for PPI + C + Metronidazole (M) 85.2% PP and 84.4% mITT. Second line 14 day therapy PPI + A + Levofloxacin had 92.3% eradication rate PP and 87.1% mITT. Ten to fourteen day Bismuth quadruple therapy was the therapy in difficult to treat patients. At the end all patients that adhered to prescribed regimens were cured of their H. pylori infection. Conclusions High dropout rate deserves further analysis. Slovenia is still a country with < 15% H. pylori resistance to clarithromycin, triple therapy with PPI plus two antibiotics reaches PP eradication rate > 85%, but mITT eradication rates are suboptimal.

APA, Harvard, Vancouver, ISO, and other styles

45

Korkin, A. L., E. V. Khomets, and S. V. Gasanova. "Analysis of the clinical course of chronic gastritis during the three-component treatment regimen of Helicobacter pylori with the inclusion of bismuthi trikalium dicitrate in the treatment." Medical Science And Education Of Ural 22, no. 1 (March 31, 2021): 87–91. http://dx.doi.org/10.36361/1814-8999-2021-22-1-87-91.

Full text

Abstract:

Purpose: to evaluate the dynamics of clinical manifestations of the disease in patients with chronic gastritis during the three-component treatment regimen of Helicobacter pylori with the inclusion of bismuthi trikalium dicitrate in the treatment. Material and methods. 38 residents of the Khanty-Mansi Autonomous Okrug-Ugra with chronic gastritis associated with Helicobacter pylori were examined in the Budgetary Establishment «Raduzhninskaya City Hospital». The clinical manifestations of dyspepsia and other manifestations of gastrointestinal dysfunction in patients before and after triple therapy with bismuthi trikalium dicitrate were evaluated. Statistical data processing was carried out using the program Statistica’ 99 Edition (Statsoft). The statistical significance of differences in different treatment periods was assessed using the Pearson – χ2 consent test and the Fisher test. The results. Clinical manifestations of the disease in the examined patients were represented by direct (58-84%) and complementary manifestations of dyspepsia (34-55%), manifestations of intestinal (32%), esophageal dysfunction (42%) in the presence of changes in general well-being (58%). When conducting eradication therapy, regression of direct manifestations of dyspepsia and heartburn is significant by the end of the first week of treatment, complementary criteria of dyspepsia – at the end of treatment. Manifestations of intestinal dysfunction in the form of constipation and discomfort in the mouth regress only 1 week after the end of therapy. Conclusion. The persistence of dyspepsia in 18% of cases after the end of eradication therapy is associated with the absence of eradication of Helicobacter pylori in 5% of cases and the functional origin of dyspepsia in 13% of cases. In patients with functional dyspepsia, the preservation of a low assessment of well-being according to the SAN questionnaire was verified, and in 5% of cases, the preservation of initial diarrhea after eradication therapy of Helicobacter pylori.

APA, Harvard, Vancouver, ISO, and other styles

46

Arnold, Donald M., and Roberto Stasi. "Does Helicobacter pylori Eradication Therapy Result in a Platelet Count Improvement in Adults with Immune Thrombocytopenic Purpura Regardless of H pylori Infection?" Hematology 2008, no. 1 (January 1, 2008): 31–32. http://dx.doi.org/10.1182/asheducation-2008.1.31.

Full text

Abstract:

AbstractA 34-year-old male with a long history of immune thrombocytopenic purpura (ITP) presents to your office. His platelet count is 30 × 109/L and he is clinically stable with no bleeding symptoms. He has read that Helicobacter pylori eradication therapy may be effective for ITP and he asks you about this. You do not have access to reliable tests for H pylori infection (e.g., urea breath test), yet you wonder about the benefit of empiric eradication therapy for your patient.

APA, Harvard, Vancouver, ISO, and other styles

47

Jonaitis, Laimas, Gediminas Kiudelis, and Limas Kupčinskas. "Gastroesophageal reflux disease after Helicobacter pylori eradication in gastric ulcer patients: A one-year follow-up study." Medicina 44, no. 3 (March 18, 2008): 211. http://dx.doi.org/10.3390/medicina44030027.

Full text

Abstract:

The aim of this study was to evaluate the course of gastroesophageal reflux disease in gastric ulcer patients after successful Helicobacter pylori eradication (group A), in patients with persistent infection after attempt to eradicate Helicobacter pylori (group B), and in control group without Helicobacter pylori eradication treatment (group C). Materials and methods. Gastric ulcer patients (n=88) were assigned either to the group receiving Helicobacter pylori eradication treatment (54 patients) or to the control group (34 patients; omeprazole treatment for 4 weeks) and were followed up for 1-year or until gastric ulcer relapsed. Gastroesophageal reflux disease was diagnosed in patients who had erosive esophagitis and/or without esophagitis if they experienced heartburn and/or regurgitation at least 2 times a week and it was associated with impairment of daily activities (Genval consensus). Results. The study was completed by 69 patients: 25 in group A, 19 in group B, and 25 in group C. At the beginning and at the end of the follow-up, gastroesophageal reflux disease was diagnosed in 10 (40%) and 9 (36%) group A patients, respectively (P>0.05); in 12 (63%) and 8 (42%) group B patients, respectively (P>0.05); and in 9 (36%) and 5 (20%) group C patients, respectively (P>0.05). At the beginning and at the end of the follow-up, reflux esophagitis was found in 3 (12%) and 5 (20%) group A patients, respectively (P>0.05); in 5 (26%) and 5 (26%) group B patients (P>0.05); in 4 (16%) and 3 (12%) group C patients (P>0.05). Conclusion. There was no statistically significant difference regarding the development of gastroesophageal reflux disease in gastric ulcer patients after Helicobacter pylori eradication, in the patients with persistent infection after attempt to eradicate, and in the control group without Helicobacter pylori eradication treatment.

APA, Harvard, Vancouver, ISO, and other styles

48

Nishizono, Akira, Takayuki Gotoh, Toshio Fujioka, Kazunari Murakami, Toshihiro Kubota, Masaru Nasu, Makoto Watanabe, and Kumato Mifune. "Serological Assessment of the Early Response to Eradication Therapy Using an Immunodominant Outer Membrane Protein ofHelicobacter pylori." Clinical Diagnostic Laboratory Immunology 5, no. 6 (November 1, 1998): 856–61. http://dx.doi.org/10.1128/cdli.5.6.856-861.1998.

Full text

Abstract:

ABSTRACT Eradication of Helicobacter pylori infection cures gastritis and prevents recurrence of peptic ulcers. Endoscopy is usually used to evaluate the effectiveness of eradication therapy. We designed a new noninvasive assay system for the early evaluation of eradication of H. pylori infection in which a crudeH. pylori outer membrane protein preparation (HPOmp) is used as an antigen, and we determined the sensitivity and specificity of the serological assay system. Immunoblot analysis showed that anti-HPOmp antibodies reacted to a protein with a molecular mass of approximately 29 kDa. In those patients who responded to therapy, the anti-HPOmp immunoglobulin G (IgG) titers measured by enzyme-linked immunosorbent assay (ELISA) at 1 month after the end of therapy were significantly lower than those before treatment (34.8% reduction;P < 0.001), and the posttreatment reduction in the antibody titer was significantly greater than that of the titer measured with a commercially available anti-H. pylori IgG ELISA (34.8% versus 16.1%; P < 0.001). When a 25% reduction of anti-HPOmp IgG titer at 1 month after the end of treatment was taken as the cutoff value for H. pylorieradication, the sensitivity and specificity of our new assay were 75% (51 of 68 treatment responders) and 96% (22 of 23 nonresponders), respectively. Our results indicate that the novel serological test with HPOmp might be a clinically useful tool for assessment of eradication of H. pylori.

APA, Harvard, Vancouver, ISO, and other styles

49

Adams, Tony. "Global eradication of poliomyelitis: Is the end of the campaign in sight?" Journal of Paediatrics and Child Health 46, no. 11 (November 2010): 619–22. http://dx.doi.org/10.1111/j.1440-1754.2009.01691.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Harris, Frederick, Sarah R. Dennison, and David A. Phoenix. "Using sound for microbial eradication - light at the end of the tunnel?" FEMS Microbiology Letters 356, no. 1 (June 12, 2014): 20–22. http://dx.doi.org/10.1111/1574-6968.12484.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Eradication. eng'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles